High Court to Review Myriad (MYGN) Patent on Genes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. ADYYF
10. DVLT

Go back to High Court to Review Myriad (MYGN) Patent on Genes

Goldman Sachs Downgrades Myriad Genetics (MYGN) to Neutral Following SCOTUS Case

December 3, 2012 9:27 AM EST

Goldman Sachs downgraded Myriad Genetics (NASDAQ: MYGN) from Buy to Neutral with a price target of $26.00 (from $34.00) after the Supreme Court of the United States (SCOTUS) agreed to hear the case against the company relating to the patentability of genes.

Given... More

Myriad Genetics (MYGN) Says U.S. Supreme Court to Hear AMP Case

November 30, 2012 4:12 PM EST

Myriad Genetics, Inc. (Nasdaq: MYGN) reported today that the Supreme Court of the United States granted certiorari agreeing to hear the case of The Association for Molecular Pathology, et al., v. Myriad Genetics, Inc., et al (Docket No. 12-398). The Supreme Court... More

Myriad Genetics (MYGN) Resumes Trading, SharesDown 4.5%

November 30, 2012 3:25 PM EST

Myriad Genetics, Inc. (NASDAQ: MYGN) resumes trading, shares down 4.5 percent on the session.... More

Myriad (MYGN) Falls; Generic Drugmakers to Get High Court Review on Patent Suits

November 30, 2012 3:22 PM EST

Myriad Genetics, Inc. (NASDAQ: MYGN) shares volatile as generic drugmakers will get U.S. high court review on patent suits.... More

Myriad Genetics (MYGN) trading halted for volatility

November 30, 2012 3:20 PM EST

Myriad Genetics, Inc. (NASDAQ: MYGN) trading halted for volatility.... More